Radient Technologies Inc.

DB:RD8 Stock Report

Market Cap: €1.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Radient Technologies Past Earnings Performance

Past criteria checks 0/6

Radient Technologies's earnings have been declining at an average annual rate of -2.8%, while the Pharmaceuticals industry saw earnings growing at 19.4% annually. Revenues have been growing at an average rate of 15.3% per year.

Key information

-2.83%

Earnings growth rate

9.87%

EPS growth rate

Pharmaceuticals Industry Growth7.33%
Revenue growth rate15.32%
Return on equityn/a
Net Margin-359.00%
Last Earnings Update31 Dec 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Radient Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:RD8 Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 223-1130
30 Sep 224-1340
30 Jun 223-1230
31 Mar 224-1340
31 Dec 214-2950
30 Sep 214-3761
30 Jun 213-3971
31 Mar 212-4291
31 Dec 208-39121
30 Sep 2017-33142
30 Jun 2018-36163
31 Mar 2018-37173
31 Dec 1913-26165
30 Sep 191-34244
30 Jun 190-31233
31 Mar 190-28212
31 Dec 180-23181
30 Sep 180-14101
30 Jun 180-1291
31 Mar 180-14110
31 Dec 170-12110
30 Sep 170-1080
30 Jun 170-970
31 Mar 170-430
31 Dec 160-420
30 Sep 161-320
30 Jun 161-430
31 Mar 161-430
31 Dec 151-1130
30 Sep 150-1130
30 Jun 150-1241
31 Mar 150-1441
31 Dec 140-841
30 Sep 140-941
30 Jun 140-831
31 Mar 140-531
31 Dec 130-531
31 Mar 130-330

Quality Earnings: RD8 is currently unprofitable.

Growing Profit Margin: RD8 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RD8 is unprofitable, and losses have increased over the past 5 years at a rate of 2.8% per year.

Accelerating Growth: Unable to compare RD8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RD8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).


Return on Equity

High ROE: RD8's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/05 13:18
End of Day Share Price 2023/03/08 00:00
Earnings2022/12/31
Annual Earnings2022/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Radient Technologies Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.